Silence Therapeutics plc
Close on Oct 19, 2026
- Market cap
- $2.77B
- P/E (TTM)
- –
- Dividend yield
- –
About Silence Therapeutics
Pharmaceutical Preparations, SIC 2834
Silence Therapeutics plc is a clinical-stage biotechnology company focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid to inhibit target gene expression. Utilizing its proprietary mRNAi GOLD discovery platform, the company engineers GalNAc-conjugated therapeutics designed to degrade specific messenger RNA transcripts in the liver, effectively silencing disease-associated proteins before synthesis. Silence Therapeutics targets rare and cardiometabolic diseases with limited therapies, advancing clinical and preclinical candidates including divesiran for hematological conditions like polycythemia vera, zerlasiran for cardiovascular disease, and SLN312 for lipid metabolism disorders.
Silence Therapeutics conducts research, development, and administrative activities across the United Kingdom and Germany. The company maintains its principal executive offices and corporate headquarters in London, United Kingdom.
Summary of the business section of Silence Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Silence Therapeutics plc
- Founded
- 1994
- Headquarters
- London, United Kingdom
- Address
- 12 Hammersmith Grove, Office 205 W6 7AP
- Phone
- 44-0-20-3457 6900
- Website
- www.silence-therapeutics.com
- Employees
- 88, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- X0
- Auditor
- PricewaterhouseCoopers LLP, Reading, United Kingdom
Stock & identifiers
- Ticker
- SLN
- Other tickers
- SLNCF
- Exchange
- Nasdaq
- IPO date
- Sep 8, 2020
- Shares outstanding
- 142M, Jul 31, 2026
- Public float
- $206.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1479615
- CUSIP
- 82686Q101
- ISIN
- US82686Q1013
- LEI
- 213800SSURRJBX85SQ91
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Rhonda Lynette Hellums | Chief Financial Officer, Director | 1,500 |
| Iain Ross | Interim PEO, Director | 39,942 |
| Craig A. Tooman | President and CEO, Director | 33,486 |
| Steven J. Romano | EVP and Chief R&D Officer | 12,993 |
| James Ede-Golightly | Director | 15,000 |
| Timothy McInerney | Director | – |
| David Lemus | Director | 7,527 |
| Michael H. Davidson | Director | 12,993 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Iain Ross | $1.27M | $1.27M | $1.07M | $40 | – |
| FY2025 Mr Tooman | $2.25M | -$1.74M | $1.07M | $40 | – |
| FY2024 Iain Ross | $0 | $0 | $1.44M | $29 | – |
| FY2024 Mark Rothera | $0 | $0 | $1.44M | $29 | – |
| FY2024 Mr Tooman | $3.69M | -$3.80M | $1.44M | $29 | – |
| FY2023 Iain Ross | $0 | $0 | $2.02M | $73 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 88 full-time employees who work primarily in the United Kingdom, Germany and the United States.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 8, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 2, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |